The Panel is led by two co-chairs: an HHS-appointed co-chair and a non-governmental co-chair. The Panel co-chairs are supported by an executive secretary and over 40 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States.

The co-chairs of the Panel provide overall leadership for Panel direction and activities; specifically, they administer and direct Panel proceedings, facilitate dynamic and productive deliberations among Panel members, and, as indicated, develop consensus recommendations and updates on the basis of objective evaluation of scientific information available in the public domain. The Panel co-chairs serve as the official voice of the Panel for public statements relating to the guidelines. The non-governmental co-chair also serves as an ex-officio member of OARAC.

The successful candidate must be a recognized leader in clinical care or clinical research in HIV and antiretroviral therapy, must have experience in clinical practice guidelines development, and must be free of any financial relationship with manufacturers of antiretroviral agents or related diagnostics.

The candidate selected will not be compensated for time commitment related to Panel activities, and travel support for participation is not provided.

Potential candidates can self-nominate or can be nominated by a colleague. The nomination should include a curriculum vitae and a letter of nomination (or letter of interest) with specific reference to how the nominee’s expertise and experience will contribute to leadership of the Panel. Please submit nominations by May 31, 2013, to Alice Pau, PharmD, Executive Secretary, Division of Clinical Research, NIAID-NIH, Bldg 10, Rm 11C103, Bethesda, MD 20892; e-mail: apau@niaid.nih.gov.

FDA Updates Atripla Labeling

“FDA recently approved updates to the Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablet label to include the following changes:

Lists Stribild as one of the drugs that should not be coadministered with Atripla